GAMMA Investing LLC Invests $110,000 in Azenta, Inc. (NASDAQ:AZTA)

GAMMA Investing LLC purchased a new position in shares of Azenta, Inc. (NASDAQ:AZTAFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,685 shares of the company’s stock, valued at approximately $110,000.

Other large investors have also recently bought and sold shares of the company. TFC Financial Management Inc. bought a new stake in shares of Azenta during the third quarter worth $25,000. Headlands Technologies LLC bought a new stake in shares of Azenta during the third quarter worth $33,000. Neo Ivy Capital Management bought a new stake in shares of Azenta during the third quarter worth $73,000. Allworth Financial LP grew its holdings in shares of Azenta by 273.1% during the fourth quarter. Allworth Financial LP now owns 1,634 shares of the company’s stock worth $106,000 after purchasing an additional 1,196 shares during the last quarter. Finally, Covestor Ltd grew its holdings in shares of Azenta by 17.5% during the third quarter. Covestor Ltd now owns 1,714 shares of the company’s stock worth $86,000 after purchasing an additional 255 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on AZTA. Stephens restated an “equal weight” rating and set a $70.00 target price on shares of Azenta in a report on Thursday, February 8th. B. Riley upped their price target on Azenta from $61.00 to $79.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Jefferies Financial Group assumed coverage on Azenta in a research note on Thursday, April 4th. They set a “hold” rating and a $64.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of Azenta in a research note on Monday, April 8th. Finally, Evercore ISI cut their price target on Azenta from $64.00 to $60.00 and set an “in-line” rating on the stock in a research note on Thursday, April 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $69.60.

Check Out Our Latest Stock Analysis on Azenta

Azenta Trading Up 1.3 %

NASDAQ:AZTA opened at $52.18 on Monday. Azenta, Inc. has a 1-year low of $36.01 and a 1-year high of $69.16. The business’s 50-day moving average price is $59.38 and its two-hundred day moving average price is $59.10. The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of -168.32 and a beta of 1.53.

Azenta (NASDAQ:AZTAGet Free Report) last released its earnings results on Wednesday, February 7th. The company reported $0.02 earnings per share for the quarter. Azenta had a positive return on equity of 0.49% and a negative net margin of 2.92%. The firm had revenue of $154.32 million for the quarter, compared to analyst estimates of $151.86 million. Sell-side analysts predict that Azenta, Inc. will post 0.27 earnings per share for the current year.

About Azenta

(Free Report)

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Recommended Stories

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTAFree Report).

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.